Free Trial
→ Market Panic: Trump Just Dropped a Bomb on Your Stocks (From American Alternative) (Ad)

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ECOZ
TrueShares ESG Active Opportunities ETF
$38.61
0.0%		$38.61
$29.80
▼
$38.78
$2.32M1.081,055 shs100 shs
EWEB
Global X Emerging Markets Internet & E-commerce ETF
$21.14
$21.14
$18.42
▼
$25.54
$2.54M0.42469 shsN/A
FNTC
Direxion Daily Fintech Bull 2X Shares
$12.75
$12.75
$9.69
▼
$23.69
$2.55M2.762,255 shsN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
$7.38
$7.38
$5.87
▼
$11.83
$2.21M0.923,034 shsN/A
2025 Gold Forecast: A Perfect Storm for Demand Cover
2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ECOZ
TrueShares ESG Active Opportunities ETF
0.00%0.00%0.00%0.00%0.00%
EWEB
Global X Emerging Markets Internet & E-commerce ETF
0.00%0.00%0.00%0.00%0.00%
FNTC
Direxion Daily Fintech Bull 2X Shares
0.00%0.00%0.00%0.00%0.00%
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ECOZ
TrueShares ESG Active Opportunities ETF
N/AN/AN/AN/AN/AN/AN/AN/A
EWEB
Global X Emerging Markets Internet & E-commerce ETF
N/AN/AN/AN/AN/AN/AN/AN/A
FNTC
Direxion Daily Fintech Bull 2X Shares
N/AN/AN/AN/AN/AN/AN/AN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ECOZ
TrueShares ESG Active Opportunities ETF
0.00
N/AN/AN/A
EWEB
Global X Emerging Markets Internet & E-commerce ETF
2.67
Moderate Buy$21.14N/A
FNTC
Direxion Daily Fintech Bull 2X Shares
0.00
N/AN/AN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ECOZ
TrueShares ESG Active Opportunities ETF
N/AN/AN/AN/AN/AN/A
EWEB
Global X Emerging Markets Internet & E-commerce ETF
N/AN/AN/AN/AN/AN/A
FNTC
Direxion Daily Fintech Bull 2X Shares
N/AN/AN/AN/AN/AN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ECOZ
TrueShares ESG Active Opportunities ETF
N/AN/A24.65∞N/AN/AN/AN/AN/A
EWEB
Global X Emerging Markets Internet & E-commerce ETF
N/AN/A25.72∞N/AN/AN/AN/AN/A
FNTC
Direxion Daily Fintech Bull 2X Shares
N/AN/A15.81∞N/AN/AN/AN/AN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/AN/A17.02∞N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ECOZ
TrueShares ESG Active Opportunities ETF
$0.280.73%N/AN/AN/A
EWEB
Global X Emerging Markets Internet & E-commerce ETF
$0.060.28%N/AN/AN/A
FNTC
Direxion Daily Fintech Bull 2X Shares
$0.040.31%N/AN/AN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/A0.12%N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ECOZ
TrueShares ESG Active Opportunities ETF
N/A
EWEB
Global X Emerging Markets Internet & E-commerce ETF
N/A
FNTC
Direxion Daily Fintech Bull 2X Shares
N/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/A

Insider Ownership

CompanyInsider Ownership
ECOZ
TrueShares ESG Active Opportunities ETF
N/A
EWEB
Global X Emerging Markets Internet & E-commerce ETF
N/A
FNTC
Direxion Daily Fintech Bull 2X Shares
N/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ECOZ
TrueShares ESG Active Opportunities ETF
N/A60,000N/ANot Optionable
EWEB
Global X Emerging Markets Internet & E-commerce ETF
N/A120,000N/ANo Data
FNTC
Direxion Daily Fintech Bull 2X Shares
N/A200,000N/ANot Optionable
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/A300,000N/AOptionable

Recent News About These Companies

CHOP, Penn advance CRISPR gene editing with fast-developed treatment for an infant with a rare disease
May 15, 2025  |  msn.comhttps://www.msn.com/en-us/science/biology/chop-penn-advance-crispr-gene-editing-with-fast-developed-treatment-for-an-infant-with-a-rare-disease/ar-AA1EQMQr
Nobel Prize winners convince court to revive CRISPR patent dispute
May 12, 2025  |  reuters.comhttps://www.reuters.com/legal/government/nobel-prize-winners-convince-court-revive-crispr-patent-dispute-2025-05-12/
Biotech investors: Stop expecting CRISPR science to make big leaps
April 14, 2025  |  statnews.comS
AI and gene editing promise ‘bespoke proteins’ for biotech
October 8, 2024  |  siliconrepublic.comS
Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
October 2, 2024  |  yahoo.comhttps://www.yahoo.com/tech/weight-loss-drug-breakthroughs-gene-090000589.html
K-12 Genome Editing at Only $2 a Pop
September 27, 2024  |  yahoo.comhttps://www.yahoo.com/tech/k-12-genome-editing-only-144035108.html
Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
August 2, 2024  |  seekingalpha.comhttps://seekingalpha.com/article/4709620-vertex-stock-came-for-cf-drugs-staying-for-gene-therapy
CRISPR can treat common form of inherited blindness, early data hint
May 15, 2024  |  msn.comhttps://www.msn.com/en-gb/health/other/crispr-can-treat-common-form-of-inherited-blindness-early-data-hint/ar-BB1mrQQG
CRISPR gene editing: in summary
March 27, 2024  |  biotechniques.comB
CRISPR Technology Takes Center Stage at SXSW 2024 for the First Time
March 8, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/crispr-technology-takes-center-stage-at-sxsw-2024-for-the-first-time-1033147575
Intellia Collaborates With ReCode To Develop Gene Therapy For Cystic Fibrosis
February 15, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/intellia-collaborates-with-recode-to-develop-gene-therapy-for-cystic-fibrosis-1033071688
CRISPR Technology: Unveiling the Breakthrough in Gene Editing and Its Far-Reaching Implications
January 18, 2024  |  techbullion.comT
Here's Why CRISPR Therapeutics Stock Rose 54% Last Year
January 15, 2024  |  msn.comhttps://www.msn.com/en-us/money/other/here-s-why-crispr-therapeutics-stock-rose-54-last-year/ar-AA1n1jau
Gene editing is now a medical reality
December 8, 2023  |  news.yahoo.comhttps://news.yahoo.com/gene-editing-now-medical-reality-224326223.html
FDA approves first use of CRISPR gene editing to treat sickle cell disease
December 8, 2023  |  news.yahoo.comhttps://news.yahoo.com/fda-approves-first-crispr-gene-173254689.html
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
December 8, 2023  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/fda-approves-first-gene-editing-cell-therapy-for-sickle-cell-disease-an-inherited-blood-disorder-1032886628
Gene Editing Will Change Medicine—and Maybe Health Investing Too
November 24, 2023  |  msn.comhttps://www.msn.com/en-us/health/other/gene-editing-will-change-medicine-and-maybe-health-investing-too/ar-AA1ksQev
CRISPR/Cas9 unlocks TuMV resistance in Chinese cabbage: A leap forward in genome-edited plant breeding
November 23, 2023  |  phys.orgP
Is CRISPR Therapeutics the Best Gene-Editing Stock?
November 22, 2023  |  msn.comhttps://www.msn.com/en-us/money/other/is-crispr-therapeutics-the-best-gene-editing-stock/ar-AA1klNrx
Three people were gene-edited in an effort to cure their HIV. The result is unknown.
November 16, 2023  |  technologyreview.comT

Media Sentiment Over Time

TrueShares ESG Active Opportunities ETF NYSEARCA:ECOZ

$38.61 -0.01 (-0.03%)
As of 07/28/2023

The TrueShares ESG Active Opportunities ETF (ECOZ) is an exchange-traded fund that is based on the S&P 500 index. The fund is an actively-managed fund that seeks total return and invests at least 80% of its assets in companies adhering to ESG best practices. ECOZ was launched on Feb 28, 2020 and is managed by TrueShares.

Global X Emerging Markets Internet & E-commerce ETF NASDAQ:EWEB

$21.14 0.00 (0.00%)
As of 06/27/2025

The Global X Emerging Markets Internet & E-commerce ETF (EWEB) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks an index of companies positioned to benefit from the advancement of internet and e-commerce technologies in emerging market countries. EWEB was launched on Nov 9, 2020 and is managed by Global X.

Direxion Daily Fintech Bull 2X Shares NYSEARCA:FNTC

$12.75 0.00 (0.00%)
As of 02/24/2023

The Direxion Daily Fintech Bull 2X Shares (FNTC) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund offers 2x daily leveraged exposure to an index of US-listed equities that offer financial technology services and decentralized finance systems. The index is selected and weighted by market-cap. FNTC was launched on Jan 20, 2022 and is managed by Direxion.

Kelly CRISPR & Gene Editing Technology ETF stock logo

Kelly CRISPR & Gene Editing Technology ETF NASDAQ:XDNA

$7.38 0.00 (0.00%)
As of 06/27/2025

The Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas